Generation Bio (GBIO)
(Delayed Data from NSDQ)
$3.12 USD
+0.06 (1.96%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $3.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
GBIO 3.12 +0.06(1.96%)
Will GBIO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GBIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GBIO
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
GBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
Generation Bio Co. (GBIO) Reports Q1 Loss, Misses Revenue Estimates
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
Other News for GBIO
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), LAVA Therapeutics (LVTX) and Aura Biosciences Inc (AURA)
Wall Street Analysts Are Bullish on Top Healthcare Picks
12 Health Care Stocks Moving In Tuesday's Intraday Session
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Generation Bio (GBIO)
Wedbush Remains a Buy on Generation Bio (GBIO)